Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Ultragenyx Pharmaceutical Inc. before investing.

In this article, we go over a few key elements for understanding Ultragenyx Pharmaceutical Inc.’s stock price such as:

• Ultragenyx Pharmaceutical Inc.’s current stock price and volume
• Why Ultragenyx Pharmaceutical Inc.’s stock price changed recently
• Upgrades and downgrades for RARE from analysts
• RARE’s stock price momentum as measured by its relative strength

About Ultragenyx Pharmaceutical Inc. (RARE)

Before we jump into Ultragenyx Pharmaceutical Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Want to learn more about Ultragenyx Pharmaceutical Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ultragenyx Pharmaceutical Inc..

Ultragenyx Pharmaceutical Inc.’s Stock Price as of Market Close

As of June 26, 2026, 10:16 AM, CST, Ultragenyx Pharmaceutical Inc.’s stock price was $30.220.

Ultragenyx Pharmaceutical Inc. is up 3.32% from its previous closing price of $29.250.

During the last market session, Ultragenyx Pharmaceutical Inc.’s stock traded between $29.360 and $30.320. Currently, there are approximately 100.60 million shares outstanding for Ultragenyx Pharmaceutical Inc..

Ultragenyx Pharmaceutical Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Ultragenyx Pharmaceutical Inc. Stock Price History

Ultragenyx Pharmaceutical Inc.’s (RARE) price is currently up 26.23% so far this month.

During the month of June, Ultragenyx Pharmaceutical Inc.’s stock price has reached a high of $30.570 and a low of $21.330.

Over the last year, Ultragenyx Pharmaceutical Inc. has hit prices as high as $42.370 and as low as $18.290. Year to date, Ultragenyx Pharmaceutical Inc.’s stock is up 31.39%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Ultragenyx Pharmaceutical Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 25, 2026, there was 1 analyst who downgraded Ultragenyx Pharmaceutical Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Ultragenyx Pharmaceutical Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Ultragenyx Pharmaceutical Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ultragenyx Pharmaceutical Inc. (RARE) by visiting AAII Stock Evaluator.

Relative Price Strength of Ultragenyx Pharmaceutical Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 25, 2026, Ultragenyx Pharmaceutical Inc. has a weighted four-quarter relative price strength of 0.90%, which translates to a Momentum Score of 59 and is considered to be Average.

Want to learn more about how Ultragenyx Pharmaceutical Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Ultragenyx Pharmaceutical Inc. Stock Price: Bottom Line

As of June 26, 2026, Ultragenyx Pharmaceutical Inc.’s stock price is $30.220, which is up 3.32% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Ultragenyx Pharmaceutical Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.